Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1958 1
1959 1
1961 2
1962 3
1963 1
1964 4
1965 11
1966 3
1967 3
1968 2
1969 3
1972 1
1974 1
1975 2
1976 2
1977 9
1978 6
1979 3
1980 9
1981 8
1982 4
1983 1
1984 5
1985 3
1986 2
1987 2
1988 3
1989 5
1990 5
1991 3
1992 2
1993 4
1994 8
1995 8
1996 5
1997 6
1998 1
1999 10
2000 4
2001 5
2002 6
2003 7
2004 17
2005 6
2006 9
2007 8
2008 8
2009 2
2010 7
2011 17
2012 12
2013 26
2014 25
2015 21
2016 15
2017 38
2018 26
2019 39
2020 33
2021 33
2022 31
2023 35
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Results by year

Filters applied: . Clear all
Page 1
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Among authors: pineda al. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Free article. Clinical Trial.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Sabatine MS, et al. Among authors: pineda al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15. Lancet Diabetes Endocrinol. 2017. PMID: 28927706 Free article. Clinical Trial.
Cranial nerve 13.
Pineda AG, Leon-Sarmiento FE, Doty RL. Pineda AG, et al. Handb Clin Neurol. 2019;164:135-144. doi: 10.1016/B978-0-444-63855-7.00009-5. Handb Clin Neurol. 2019. PMID: 31604543 Review.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Bonaca MP, et al. Among authors: pineda al. Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133605 Free article. Clinical Trial.
A man with sudden onset chest pain.
Pineda A, Parker CW, Colla JS. Pineda A, et al. J Am Coll Emerg Physicians Open. 2022 Apr 9;3(2):e12708. doi: 10.1002/emp2.12708. eCollection 2022 Apr. J Am Coll Emerg Physicians Open. 2022. PMID: 35425941 Free PMC article. No abstract available.
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
Franchi F, Ortega-Paz L, Rollini F, Been L, Rivas A, Maaliki N, Zhou X, Pineda AM, Suryadevara S, Soffer D, Zenni M, Angiolillo DJ. Franchi F, et al. Among authors: pineda am. EuroIntervention. 2023 Mar 20;18(15):1254-1265. doi: 10.4244/EIJ-D-22-00719. EuroIntervention. 2023. PMID: 36602868 Free PMC article. Clinical Trial.
556 results